Researchers at Queen Mary University of London have led the clinical development of the first non-integrase strand-transfer inhibitor (INSTI) single tablet treatment for HIV, among growing concern for the potential of widespread INSTI-resistance in resource limited settings. The results of the landmark phase 3 trial, published in The Lancet, show that the once-daily, single tablet combination of doravirine with islatravir is an effective and safe treatment for HIV.
This article was originally published on MedicalXpress.com
